**The big picture:** BioMarin Pharmaceutical Inc. has appointed Cara Bauer, Ph.D., as its new Executive Vice President, Chief People Officer, succeeding retiring Amy Wireman. **Why it matters:** This leadership change underscores a strategic focus on human resources and talent development within the biopharmaceutical sector, crucial for scaling organizations and fostering innovation. **Between the lines:** - Ms. Bauer brings over 25 years of HR experience from biopharmaceutical and technology industries, including roles at Kyverna Therapeutics, Kite (a Gilead company), Riot Games, Netflix, Amgen, and Novo Nordisk. - Her appointment is effective October 5, 2026, with previous CPO Amy Wireman transitioning to an advisory role. - BioMarin's CEO highlighted Bauer's track record in driving large-scale transformation and building high-performing organizations. **Staffing & HR impact:** This move signals BioMarin's commitment to strengthening its organizational capabilities and talent pipeline, potentially influencing future recruitment strategies and internal HR investments. The transition also highlights the importance of succession planning for critical executive roles. **The bottom line:** BioMarin is investing in experienced HR leadership to support its growth and innovation in the rare disease biotechnology space.